EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development and Validation of a Simultaneous HPLC Stability-Indicating Method for Atorvastatin and Apigenin in a Novel SMEDDS Formulation Using Quality by Design (QbD) Approach

Sarmad Abdulabbas Kashmar, Reem Abou Assi, Muqdad Alhijjaj, Siok Yee Chan

Processes · 14.09.2025 · 13 (9) · 2933

DOI: 10.3390/pr13092933 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Processes, online erschienen am 14.09.2025. Verfasst von Sarmad Abdulabbas Kashmar und 3 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Higher Education Malaysia Fundamental Research Grant Scheme.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atorvastatin (ATV), a widely used statin, exhibits both cholesterol-lowering and anti-inflammatory effects. Apigenin (API), a natural flavonoid, also demonstrates potent anti-inflammatory activity. This study aimed to develop and validate a novel stability-indicating reverse-phase HPLC method for the simultaneous quantification of ATV and API in standard solutions and dual ATV–API-loaded self-microemulsifying drug delivery system (SMEDDS). Quality by Design (QbD) approach was used to define the quality target product profile (QTPP), critical quality attributes (CQAs), and identify critical method parameters (CMPs) through risk assessment. A central composite design (CCD) evaluated the effects of organic phase ratio, buffer pH, and flow rate on chromatographic responses, including retention time, tailing factor, and resolution. Separation was achieved using an Agilent Eclipse XDB C-18 column (5 µm, 4.6 × 150 min) with a mobile phase of acetonitrile and 0.1 M ammonium acetate buffer (pH 7.0) in a 40:60 (v/v) ratio, UV detection at 266 nm, and a flow rate of 0.4 mL/ min. The method met ICH and USP (2021) validation criteria, showing excellent linearity (0.1–10 µg/mL), precision, accuracy, and specificity. No interference from SMEDDS excipients or degradation products during stability studies was observed. This validated method offers a reliable tool for formulation development and routine analysis of ATV and API combinations

Förderung

  • Ministry of Higher Education Malaysia Fundamental Research Grant Scheme

Zitieren

APA

Kashmar, S. A., Assi, R. A., Alhijjaj, M., & Chan, S. Y. (2025). Development and Validation of a Simultaneous HPLC Stability-Indicating Method for Atorvastatin and Apigenin in a Novel SMEDDS Formulation Using Quality by Design (QbD) Approach. Processes, 13(9), 2933. https://doi.org/10.3390/pr13092933

Vancouver

Kashmar SA, Assi RA, Alhijjaj M, Chan SY. Development and Validation of a Simultaneous HPLC Stability-Indicating Method for Atorvastatin and Apigenin in a Novel SMEDDS Formulation Using Quality by Design (QbD) Approach. Processes. 2025;13(9):2933. doi:10.3390/pr13092933

BibTeX
@article{Kashmar2025,
  author = {Kashmar, Sarmad Abdulabbas and Assi, Reem Abou and Alhijjaj, Muqdad and Chan, Siok Yee},
  title = {Development and Validation of a Simultaneous HPLC Stability-Indicating Method for Atorvastatin and Apigenin in a Novel SMEDDS Formulation Using Quality by Design (QbD) Approach},
  journal = {Processes},
  year = {2025},
  volume = {13},
  number = {9},
  pages = {2933},
  doi = {10.3390/pr13092933}
}
Kostenlos starten →